Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who undergo hepatic surgery.
Get full access to this article
View all access options for this article.
References
1.
Mahgoub A., Idle JR, Dring LC, Lancaster R. & Smith RLPolymorphic hydroxylation of debrisoquine in man. Lancet1977; 2: 584-86.
2.
Kimura S., Umeno M., Skoda RC, Meyer UA & Gonzalez FJThe human debrisoquine 4-hydroxylase (CYP2D) locus sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. American Journal of Human Genetics1989; 45: 889-905.
3.
Cholerton S. , Daly AK & Idle JRThe role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological Science, 1992; 13: 434-9.
4.
Eichelbaum M. & Gross ASThe genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects . In Pharmacogenetics of Drug Metabolism. Kalow W (ed), 1992; Pergamon Press Inc: New York, pp. 625-48.
5.
Ayesh R. & Smith RLGenetic polymorphism in human toxicology. In Recent Advances in Clinical Pharmacology and Toxicology. Turner P & Volans GN (eds), 1989; Churchill Livingstone, 4: 137-57.
6.
Pugh Rnh, Murray-Lyon IM, Dawson JL, Pietroni MC & Williamson R.Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery1973; 60: 646-9.
7.
Hobscher SG, Clements D., Elias E. & McMaster P.Biopsy findings in cases of rejection of liver allograft. Journal of ClinicalPathology1985; 38: 1366-73.
8.
Calne RY, McMaster P., Portmann B., Wall WJ & Williams R.Observations on preservation, bile drainage and rejection in 64 human orthotopic liver grafts. Annals of Surgery1977; 186: 282-90.
9.
Idle JR, Mahgoub A., Angelo MM, Dring LG, Lancaster R. & Smith RLThe metabolism of [14C]-debrisoquine in man. British Journal of Clinical Pharmacology1979; 7: 257-66.
10.
Sloan TPProperties of oxidation polymorphism in man with particular reference to the disposition of debrisoquine, phenacetin and phenytoin. Ph.D. Thesis, 1980, University of London, England, UK.
11.
Evans Dap, Mahgoub A., Sloan TP, Idle JR & Smith RLA family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of MedicalGenetics1980; 17: 102-5.
12.
Evans Dap, Harmer D., Downham DY, Whibley EJ, Idle JR, Ritchie J. & Smith RLThe genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. Journal of MedicalGenetics1983; 20: 321-9.
13.
Mitchell SC & Haley CSDebrisoquine hydroxylation phenotyping: do we expect too much?Lancet1990; 2: 694.
14.
Idle JRPoor metabolisers of debrisoquine reveal their true colours. Lancet1989; 2: 1097.
15.
Lanthier PL , Reshef R., Shah RR, Oates NS, Smith RL & Morgan MYOxidation phenotyping in alcoholics with liver disease of varying severity. Alcoholism ( N.Y.) 1984; 8: 435-41.
16.
Bertilsson L., Dahl ML, Sjoqvist F., Aberg-Wistedt A., Humble M., Johansson I., Lundqvist E. & Ingelman-Sundberg M.Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet1993; 341: 63.
